In the News
Reuters: Novartis taps into gene editing for next generation drugs
Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.
PharmaTimes: Novartis in genome editing pacts with Intellia, Caribou
Novartis is buying into CRISPR gene editing technology via two separate deals with Intellia Therapeutics and Caribou Biosciences.
UC Berkeley News Center: Jennifer Doudna elected to the National Academy of Inventors
Three UC Berkeley, faculty members whose innovations have launched new startups and whole new areas of research have been named fellows of the National Academy of Inventors.
Xconomy: With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray
Add another entrant to the race toward what might be called Gene Therapy 2.0. Atlas Venture and the research arm of the drug giant Novartis (NYSE: NVS) have put $15 million into the Series A round for Intellia Therapeutics, which is emerging today from stealth after two years of incubation.
Breakthrough Prize: Jennifer Doudna wins one of the 2015 Breakthrough Prizes in Life Sciences
The Breakthrough Prize Foundation tonight announced the recipients of the 2015 Breakthrough Prizes in Fundamental Physics and Life Sciences. These distinguished winners, along with previously announced recipients in the Mathematics category, each receive a $3 million prize.